Skip to main content

Table 3 Effect of omega-3 on cardiometabolic indices in diabetic patients with NAFLD

From: Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial

Indices

Omega-3 (n = 30)

Placebo (n = 30)

P

P††

AIP

   

0.13

 Baseline

0.49 ± 0.22

0.44 ± 0.19

0.36

 Week 12

0.38 ± 0.28

0.41 ± 0.27

0.67

P

0.007

0.33

 

 Mean change

−0.11 ± 0.20

−0.03 ± 0.16

0.10

Castelli risk index I

   

0.46

 Baseline

3.63 ± 0.9

3.41 ± 0.7

0.31

 Week 12

3.38 ± 0.9

3.34 ± 0.7

0.88

P

0.05

0.62

 

 Mean change

−0.25 ± 0.6

−0.07 ± 0.7

0.29

Castelli risk index II

   

0.70

 Baseline

2.11 ± 0.6

1.97 ± 0.5

0.55

 Week 12

1.87 ± 0.6

1.83 ± 0.5

0.81

P

0.01

0.15

 

 Mean change

−0.24 ± 0.5

−0.14 ± 0.5

0.47

AC

   

0.40

 Baseline

2.63 ± 0.9

2.41 ± 0.7

0.31

 Week 12

2.38 ± 0.9

2.34 ± 0.7

0.88

P

0.05

0.62

 

 Mean change

−0.25 ± 0.6

−0.07 ± 0.7

0.29

  1. P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD)
  2. P: resulted from comparisons within groups by paired t-test
  3. P: resulted from comparisons between two groups by independent t-test
  4. P††: resulted from comparing the mean change from baseline between groups using univariate ANCOVA after adjusting for energy intake and weight change
  5. NAFLD Non-alcoholic fatty liver disease, AIP Atherogenic index of plasma, AC Atherogenic coefficient